Pfizer Trying A Novel Oncology Business Unit To Maximize Its Novel Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms that show significant promise. Now the company is trying a novel business arrangement to try to make the most of what it has.
You may also be interested in...
Pfizer Restructures for a More Flexible Future
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.
Predicting Success: The Easiest, And Hardest Routes To Market
A new analysis from BIO, Informa Pharma Intelligence and QLS looks at clinical drug development activity from the past decade, looking at the most (and least) successful areas. Infographic depicts key trends and details.
Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: